HIMS241011C21000
- 0.15
- +0.10+200.00%
Hims & Hers Health Newsroom
Citi Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Maintains Target Price $20
B of A Securities Maintains Buy on Hims & Hers Health, Lowers Price Target to $20
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Cuts Target Price to $20
Citi Downgrades Hims & Hers Health(HIMS.US) to Hold Rating, Maintains Target Price $20
Hold Rating on Hims & Hers Health Amid Competitive Threats From Lilly's Zepbound
Needham Initiates Hims & Hers Health(HIMS.US) With Buy Rating, Announces Target Price $24
Hims & Hers Health Analyst Ratings
Hims & Hers Health (HIMS): A Buy Rating on Strong Growth and Market Positioning
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS) and RxSight (RXST)
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $24
Deutsche Bank Adjusts Hims & Hers Health Price Target to $23 From $16, Maintains Hold Rating
Leerink Partners Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Cuts Target Price to $21
Hold Rating on Hims & Hers Health Amid Revenue Uptick and Market Uncertainties
Seaport Global Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Raises Target Price to $28
Hims & Hers Health Analyst Ratings
Piper Sandler Reiterates Neutral on Hims & Hers Health, Maintains $18 Price Target
A Quick Look at Today's Ratings for Hims & Hers Health(HIMS.US), With a Forecast Between $18 to $28
Piper Sandler Keeps Their Hold Rating on Hims & Hers Health (HIMS)
Hims & Hers Health: Strong Q2 Performance and Positive Outlook Reinforce Buy Rating
Hold Rating on Hims & Hers Health Amid GLP-1 Market Uncertainties and Competitive Pressures